engage checkpoint medical linkedin twitter

The Role of PARPi in Prostate Cancer: Experts Knowledge Share

The Role of PARPi in Prostate Cancer: Experts Knowledge Share

Prof. Emmanuel S. Antonarakis, Dr Neal D. Shore, Dr Andrew J. Armstrong

Portrait of Emmanuel S. Antonarakis
Prof. Emmanuel S. Antonarakis

Medical Oncologist

Johns Hopkins Medicine

United States (US)

Portrait of Neal D. Shore
Dr Neal D. Shore


Carolina Urologic Research Centre and GenesisCare

United States (US)

Dr Andrew J. Armstrong

Medical Oncologist

Duke University School of Medicine

United States (US)

preview next

time | open 5 min | Aug 2020

This programme was made for you:   your opinion matters

Share your feedback in just 4 clicks and help us to continue to create the content you need.

I agree that this educational programme:

On August 26th and August 28th 2020, two Experts Knowledge Share interactive webinars connected global participants with renowned panel experts to discuss the therapeutic role of PARP inhibitors in prostate cancer. Panellists included Dr. Neal D. Shore (Programme Chair), Prof. Andrew J. Armstrong, and Prof. Emmanuel S. Antonarakis.


Key topics included:

  • Prevalence of DDR mutations in prostate cancer, and somatic and germline testing

  • PARPi mechanism of action

  • Recent clinical trial data and ongoing studies

  • Efficacy and safety profiles of PARPi

  • Patient case studies


In this video, Dr. Neal D. Shore summarises this Experts Knowledge Share programme and the expanding role for PARP inhibitors in prostate cancer therapy. Follow the link above to access the accredited e-learning associated with the programme.


Other programmes of interest

Other programmes developed by Dr Neal D. Shore

Other programmes developed by Dr Andrew J. Armstrong